bioRxiv · 17 Nov 2026
Drug Repurposing of Rapamycin Mitigates Amyloid-β-Associated Proteotoxicity in Caenorhabditis elegans Models of Alzheimer's Disease
Samirah Alkhudaydi, Abdullatif Alsulami, Makayla Linfoot, Megan Terlouw, Ava Holzer, Faisal Albalawi, Stephanie McGrath, Julie Moreno
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Background: Alzheimers disease (AD) is the leading cause of dementia worldwide, affecting an estimated 55 million people and projected to exceed 130 million by 2050. AD is defined pathologically by extracellular accumulation of amyloid-beta (A{beta}) and intracellular neurofibrillary tangles. Currently no therapy halts the underlying neurodegeneration in AD patients. Proteotoxic accumulation of A{beta} is a central pathogenic event therefore, strategies that enhance its clearance represent a compelling therapeutic avenue. Rapamycin (sirolimus), an FDA-approved allosteric inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1) that relieves mTORC1-mediated suppression of autophagy, positioning it as an attractive drug-repurposing candidate for AD. However, it remains unclear whether rapamycins neuroprotection depends on directly reducing A{beta} burden or acts through A{beta}-independent mechanisms. This question, along with whether rapamycin alters specific A{beta} species, has not been systematically examined in a single, genetically tractable model. Methods/Results: Using two transgenic C. elegans models of human A{beta} expression a temperature-inducible, muscle-specific strain CL4176 and the pan-neuronal strain CL2355. We exposed C. elegans to 20 M rapamycin the lowest, nontoxic concentration to produce a protective effect. Rapamycin treatment delayed A{beta} induced paralysis in log-rank p = 0.0001) and improved crawling and swimming locomotion parameters. In the pan-neuronal CL2355 strain, rapamycin rescued the A{beta} induced chemotaxis deficit (one-way ANOVA, p = 0.008) without altering chemotaxis in the non-transgenic CL2122 control. Rapamycin also extended Kaplan Meier survival in CL2355 and preserved locomotor health span, delaying the trajectory of age related motor decline. At the molecular level, rapamycin did not significantly affect A{beta} burden. Conclusion: Rapamycin provides broad-spectrum and A{beta}-selective neuroprotection across muscle and neuron expressing C. elegans models of A{beta} proteotoxicity, extending from paralysis and locomotion to chemosensory behavior, longevity, and health span.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (0)
What it cites, from open citation data, with Crossref's record of each.